Predictive value of direct bilirubin and total bile acid in lung adenocarcinoma patients treated with EGFR-TKIs

BMC Pulmonary Medicine

Table 1 Distribution of basic characteristics according to ALP, DB and TBA group in lung adenocarcinoma patients treated with EGFR-TKIs

Characteristics	Total (n=131)	ALP≤124 U/L (n=100)	ALP>124 U/L (n=31)	p-value	DB≤3.3 μmol/L (n=80)	DB>3.3 μmol/L (n=51)	p-value	TBA≤4.0 μmol/L (n=73)	TBA>4.0 μmol/L (n=58)	p-value	HDL-H≤1.3 mmol/L (n=86)	HDL-H>1.3 mmol/L (n=45)	P-value
Gender
Female	84	69	15	0.053	55	29	0.193	34	50	0.091	49	35	0.030
Male	47	31	16		25	22		12	35		37	10
Age
≤60 years	84	60	24	0.077	57	27	0.041	27	57	0.341	58	26	0.273
>60 years	47	40	7		23	24		19	28		28	19
Smoking
No	101	81	20	0.085	67	34	0.032	37	64	0.664	64	37	0.313
Yes	30	19	11		13	17		9	21		22	8
ECOG PS status
0	42	35	7	0.295	26	16	0.171	19	23	0.094	33	9	0.058
1	65	50	15		36	29		20	45		42	23
2	13	8	5		8	5		6	7		8	5
3	11	7	4		10	1		1	10		4	7
Bone metastasis
No	100	76	24	0.871	60	40	0.652	35	65	0.961	69	31	0.260
Yes	31	24	7		20	11		11	20		18	13
Liver metastasis
No	124	95	29	0.754	77	47	0.310	44	80	0.709	83	41	0.594
Yes	7	5	2		3	4		2	5		4	3
EGFR mutation status
Exon 19 deletion	67	46	21	0.057	41	26	0.257	24	43	0.377	50	17	0.111
Exon 21 L858R	56	46	10		32	24		21	35		33	23
Others	8	8	0		7	1		1	7		4	4
Treatment history for hyperlipidemia
No	122	94	28	0.479	76	46	0.289	41	81	0.183	82	40	0.475
Yes	9	6	3		4	5		5	4		5	4
EGFR TKI
Gefitinib	40	32	8	0.715	25	15	0.386	13	27	0.624	29	11	0.618
Icotinib	63	48	15		41	22		21	42		40	23
Others	28	20	8		14	14		12	16		18	10
Chemotherapy
No	95	73	22	0.821	63	32	0.070	32	63	0.682	65	30	0.278
Yes	36	27	9		17	19		14	22		21	15
Line
First	101	76	25	0.807	57	44	0.056	39	62	0.135	67	34	0.761
Second	30	24	6		23	7		7	23		19	11

ISSN: 1471-2466